Monoclonal antibodies to the envelope proteins (E) of the 17D vaccine strain of yellow fever virus (17D YF) and to dengue 2 virus were examined for their ability to confer passive protection against lethal 17D YF encephalitis in mice. All 13 IgG anti-17D YF antibodies, regardless of neutralizing capacity, conferred solid protection when given in a relatively high dose prior to intracerebral inoculation of virus. Three antibodies with high in vitro neutralizing titres were all protective at a low dose as were several non-neutralizing antibodies. One flavivirus group-reactive antibody to dengue 2 virus conferred similar protection at low dose. Protection was also observed when antibodies were given several days after virus inoculation when peak infectious virus titres and histopathological evidence of infection were present in brains. The ability of a non-neutralizing antibody to protect could not be attributed to complementdependent lysis of virus-infected cells and did not correlate with avidity or with proximity of its binding site to a critical neutralizing epitope of the E protein. Some antibodies, characterized as non-neutralizing by plaque reduction assay on Vero cells, inhibited the growth of virus in a mouse neuroblastoma cell line, suggesting one possible mechanism of protection. These results may be relevant to the design of prospective flavivirus vaccines and support the possibility of conferring broadened protection among flaviviruses by stimulating the antibody response to appropriate epitopes of the E protein.
INTRODUCTION
Earlier studies on protection of experimental animals from challenge with alphaviruses or flaviviruses have frequently noted a lack of correlation between neutralizing antibody levels and protection, especially when cross-protection has been examined (Porterfield, 1980) . Recently, monoclonal antibodies, usually characterized by an association of type or strain specificity with high-titred neutralizing activity, have been used in passive protection models. Among alphaviruses, studies with Sindbis virus (Schmaljohn et al., 1982) , Venezuelan equine encephalitis virus (Mathews & Roehrig, 1982) and Semliki Forest virus (SFV) (Boere et al., 1985) indicated that some non-neutralizing antibodies, as well as neutralizing antibodies, were protective in vivo against lethal encephalitis. Among flaviviruses, only neutralizing antibodies protected against challenge with tick-borne encephalitis virus (Heinz et al., 1983) and solid protection against St. Louis encephalitis virus was conferred only by a type-specific high titre neutralizing antibody (Mathews & Roehrig, 1984) .
The 17D strain of yellow fever virus (17D YF), attenuated from the wild Asibi strain by passage in eggs, is unique as a safe, widely used, single dose vaccine that confers long lasting immunity against a flavivirus infection. Attempts at development of satisfactory vaccines against other flaviviruses such as dengue and Japanese encephalitis viruses by similar methods have been less successful. 
METHODS
Antibodies. The monoclonal antibodies to 17D YF that were used have been described previously : Monath et al., 1984 . They have been grouped into several categories according to strain, type or ftavivirus group specificity as well as by biological activity and they define eight antigenic sites on the envelope glycoprotein of 17D YF . One antibody, 5E5, originally classified as group-reactive has been subsequently re-classified as type-specific (Monath et al., 1984) . The monoclonal antibodies and control mouse myeloma proteins PC-5 (lgG2a) or MOPC-21 (lgG t ) used in the present experiments were in the form of immune ascitic fluids. The total protein content of each ascitic fluid was estimated by Coomassie Brilliant Blue assay (Sigma) and electrophoresis on cellulose acetate membranes was performed. The preparations were then scanned and the areas under the curves integrated by densitometry. The monoelonal antibody peaks were identified and the protein concentrations of these were calculated as a percentage of the total protein. Antibodies were defined as neutralizing on the basis of 90°,~ or greater plaque reduction (PR NToo) of 17D YF on Vero cell monolayers in the absence of complement. Although some of the antibodies classified as non-neutralizing gave lesser degrees of plaque reduction at dilutions of 1 : 20 to 1 : 320 with or without the addition of complement, they were clearly distinct from the neutralizing antibodies which all had PRNT9o titres of 1:10000 or greater. The dengue 2 virus antibodies were provided by Dr W. E. Brandt and have also been described previously .
Protection studies. Strain 17D YF vaccine (Lot NK 3198, Connaught Laboratories, Swiftwater, Pa., U.S.A.) was passaged in Vero cells to produce a virus pool with a titre of 2.5 x 107 p.f.u./ml by assay on Vero monolayers. In preliminary experiments, 6-week-old BALB/c or Swiss (CD-1) mice were inoculated intracerebrally with 0.040 ml of undiluted virus or with serial 10-fold dilutions, corresponding to an inoculum from 106 to 10 ~ p.f.u./mouse. Ruffled fur and hind leg weakness were evident by day 7 post-infection and death occurred between days 8 and 14. Eighty-five°o of the deaths occurred between days 9 and 11. Because mortality of more than 90°.o was observed only with 10 (~ p.f.u., this dose was used for passive protection experiments. Mortality of 70 to 75 °..o was observed at doses of i(15 to 103 p.f.u., 470o at 10 z p.f.u, and 13~ at 10 ~ p.f.u. For most passive protection experiments, 6-weekold mice were injected intraperitoneally with dilutions of immune ascitic fluids or control myeloma proteins 24 h prior to intracerebral challenge with virus. In some experiments antibodies were given 3, 4 or 5 days after virus challenge. Results of both preliminary challenge experiments and passive protection experiments were similar with BALB/c and with Swiss mice and the numbers were combined.
E{l~ct o/antibodies on growth ~/17D YF in neuroblastoma cells. Mouse neuroblastoma cells, clone Neuro-2a (American Type Culture Collection) were grown in MEM containing I0°~ foetal calf serum (MEM-FCS) with non-essential amino acids. Because 17D YF does not form plaques on these cells, a conventional plaque reduction assay could not be performed. Instead, monoclonal antibody at 1:1000 final dilution, rabbit complement (Accugenics, Inc.) at 1:20 final dilution, or heat-inactivated complement, and virus at a multiplicity of infection of 1.0 were mixed, incubated at 37 >C for 90 min and added to neuroblastoma cell monolayers. After 90 rain at 37~C, the wells were washed three times with phosphate-buffered saline and incubated at 37 ~C. After 48 h of incubation, the supernatants were removed and titrated for infectious virus using the standard Vero ceil plaque assay.
RESULTS

Protection studies
The results of passive protection experiments with antibodies given 24 h prior to challenge with virus are summarized in Table 1 . Mortality in controls was 92~J~. The only IgM antibody, 8A3, conferred no protection against challenge although it has a high titre of neutralizing activity. All the IgG antibodies to 17D YF, regardless of specificity or neutralizing capacity, conferred solid protection at 400 jag, the highest dose administered. The three neutralizing IgG antibodies protected well at a dose of 4 ~g. Taken individually, they did not confer statistically significant protection at the 0.4 ~tg dose but, if the results at that dose are combined (11 of 36 mice survived), protection by these three antibodies was significant (P < 0.05). Among the nonneutralizing monoclonal antibodies, most offered no significant protection at less than 40 ~tg but three of them, 4El, 5E3 and 3E9, conferred protection at a 4 jag dose, similar to the high titre neutralizing antibodies. Among the dengue monoclonal antibodies, 4G2, a group-reactive antibody with a low neutralization titre against dengue 2 virus, also protected at the 4 gg dose. 7/8 2/7 3H5 0/6 * (+), 90°o or greater plaque reduction in Vero cells at dilutions of l :10000 to l :100000: (-), no plaque reduction or less than 90°o reduction at dilutions 1:20 to I :320.
I" Mortality in controls was 92°~, :~ A, Strain-specific, neutralized 17D YF only; B, type-specific for YF, neutralized 17D YF and Asibi YF; C, type-specific, neutralized Asibi YF onlY', D, flavivirus group-reactive, neutralized Asibi YF but not 17D YF; E, type-specific, no neutralizing activity.
§ Antibody protein (~tg)/mouse. Antibody was given intraperitoneally at 24 h prior to intracerebral challenge with 17D YF.
I[ 4G2 and I B8 are flavivirus group-reactive, neutralize dengue virus in low titre. 3H5 is dengue 2 virus-specific, neutralizes in high titre . Monoclonal antibody 1B8, another dengue 2 group-reactive antibody, protected only at 400 lag and 3H5, a high titre dengue 2-specific neutr/tlizing antibody, conferred no protection.
To determine if passive administration of antibody could alter the course of established infection, antibodies were given 3, 4 or 5 days after intracerebraI challenge with virus. The results are summarized in Table 2 . Both a neutralizing (2El0) and a non-neutralizing (3E9) antibody conferred protection when given at a dose of 400 lag at day 3. Two of the three neutralizing antibodies, and antibody 3E9, also protected when given at a dose of 40 lag on day 4. Antibodies 4G2 and 2E 10 were less effective but may have given marginal protection. Antibody 3E9 conferred partial protection when given at a dose of 400 gg at day 5. To ascertain that infection was indeed established at the time that antibodies were given, the course of infection was better defined by removing brains from control mice at days 0 (4 h after inoculation), 3, 4 and' 5, and at day 8 from moribund mice. Brains were either homogenized in MEM-FCS and titrated for infectious virus on Veto cell monolayers or were fixed in 10~ buffered formalin for histological examination. Virus titre increased between days 0 (l-6 x 103 p.f.u./g brain tissue) and 3 (1.9 x 104 p.f.u./g), peaked at days 4 (6 x l0 s p.f.u./g) and 5 (5-2 x l0 s p.f.u./g) and declined by day 8 (3.6 x 104 p.f.u./g). Histopathological alterations indicative of infection were detected sometimes as early as 3 days after virus injection. These were characterized by perivascular lymphocytic infiltration, gliosis and spongiosis occurring in small zones adjacent to, but distant from, the inoculation tract. By day 4 unequivocal encephalitis was evident with bilateral multifocal areas of neuronal necrosis often associated with spongiosis, localized gliosis and perivascular inflammation. On day 8, perivascular inflammation was less conspicuous but cellular necrosis and gliosis were widespread throughout the cortex and hippocampus. Degenerating neurons had a characteristic appearance of nuclear karyorrhexis and cytoplasmic contraction and hypereosinophilia so that eventually only an eosinophilic mass with or without small amounts of granular nuclear debris was evident.
Effects of antibodies on virus growth in neural cells
Because a mechanism of protection by antibodies defined as non-neutralizing in conventional assays was not apparent, the possibility that they might affect the growth of virus in a neural cell line was examined. We had previously determined that although some of our monoclonal antibodies to the non-structural 17D-specified protein gp48 did lyse virus-infected cells in the presence of complement (Schlesinger et al., 1985) , none of the monoclonal antibodies to the E protein was capable of doing so. Antibody 3E9 had previously been tested repeatedly in standard plaque reduction assays in Vero cells and gave no neutralization at 1:30 to 1:50 dilutions with or without the addition of complement. Antibody 4G2 gave no plaque reduction in Vero cells in the absence of complement but gave reduction of 95 ~ at 1:200 dilution and 80~ at 1 : 2000 with complement. Mixtures of 3E9 or 4G2, virus and complement or heat-inactivated complement were incubated at 37 °C and added to Neuro-2a cell monolayers. Supernatants from these cultures were sampled at 48 h and titrated for infectious virus by standard plaque assay on Vero cell monolayers as described in Methods. Results are summarized in Table 3 , experiment l. Under these conditions, antibody 3E9 caused 90~o reduction of virus yield in Neuro-2a cells in the presence of complement but no significant reduction in the absence of complement. Antibody 4G2 caused more than 99 ~o reduction of virus yield with complement and more than 90~ without complement. A high titre neutralizing monoclonal antibody, 2El0, caused a marked reduction of virus yield in Neuro-2a cells with or without complement in this assay. Antibodies 5H3 and 4El which gave no neutralization at low dilution with or without complement in standard Veto cell plaque reduction assay, were tested similarly in a second experiment (Table 3 , experiment 2). Antibody 5H3 caused 98~o reduction in virus yield with complement and 81 ~ without complement whereas antibody 4El gave only slight reduction in virus yield.
DISCUSSION
Our results are similar to previous studies of encephalitis using monoclonal antibodies in that high-titred IgG neutralizing antibodies as conventionally defined were effective in conferring passive protection against virus challenge. They differ, however, in that all of our IgG antibodies, regardless of neutralizing capacity, avidity or epitope specificity, conferred solid protection when given in relatively high dose. A high degree of protection by non-neutralizing monoclonal antibodies has been associated with the ability of antibody to lyse virus-infected cells in vitro in the presence of complement (Schmaljohn et al., 1982; Boere et al., 1985) , or with high avidity and proximity to a critical neutralizing epitope (Mathews & Roehrig, 1982) . Other possible mechanisms of protection have been suggested. Monoclonal antibodies to SFV, defined as non-neutralizing by plaque reduction, were shown to reduce growth of virus in L cells in a different assay. The authors suggested that this 'growth inhibition' as well as possible enhanced uptake of SFV in mouse macrophages mediated by non-neutralizing antibodies might offer other explanations for protection (Boere et al., 1985) . With SFV, the route of challenge was intraperitoneal. Our non-neutralizing anti-E antibodies did not lyse virus-infected neural cells, and their protective capacity did not correlate with high avidity or with their proximity to a critical neutralizing epitope as determined by a competitive binding assay . Therefore, a mechanism(s) of protection by these antibodies was not apparent. Although they do enhance the infectivity of the virus in macrophages, probably through increased uptake (Schlesinger & Brandriss, 1983) , the intracerebral route of challenge used in these experiments would make this an unlikely explanation for protection. Further investigation with some of them revealed that although they had little or no capacity to reduce plaque formation in a standard Veto cell assay (a commonly used definition of neutralization) they did inhibit growth of virus in a mouse neural cell line, an observation that might be related to their ability to confer protection in an encephalitis model. Because some of these antibodies are comparable in protective capacity to those with high titre neutralizing activity, as usually defined, they may be of interest in regard to mechanisms of resistance to viral infection. It is possible that the epitopes to which they are directed might also be useful in addition to critical neutralizing epitopes as candidates for incorporation into synthetic or recombinant vaccines.
The high degree of cross-protection against l 7D YF conferred by a dengue 2 virus monoclonal antibody may be of particular interest. This observation supports the possibility that it might be feasible to stimulate the immune response to cross-reactive epitopes as well as to type-specific ones in an attempt to confer broadened protection against flaviviruses. It is worth noting that although the anti-dengue virus monoclonal antibody 4G2 as well as some of the other nonneutralizing antibodies compete with neutralizing antibodies in competitive binding assays they do not interfere with neutralization of 17D YF.
A possible drawback to this approach exists in the case of dengue virus where the ability of both type-specific and group-reactive monoclonal antibodies to enhance virus growth in macrophages has been postulated to contribute to the pathogenesis of dengue shock syndrome (Halstead et al., 1984) . Whether or not this is correct, there is no evidence at present that this potential problem exists for other flaviviruses.
The ability of both neutralizing and non-neutralizing monoclonal antibodies to protect when given 3 to 5 days after viral challenge when pathological changes were present and virus was multiplying in brain suggests a role of antibody in recovery from infection in addition to prevention. There is some precedent for this observation. Passive administration of immune serum containing neutralizing antibody has been shown to increase survival of mice after challenge with West Nile virus (Camenga et al., 1974 ), 17D YF (Zisman et al., 1971 or Sindbis virus (Griffin & Johnson, 1977) when given early in the course of infection. Monoclonal antibodies to SFV also reduced mortality in mice up to 48 h after intraperitoneal challenge with virus (Boere et al., 1985) . Using monoclonal antibodies to St. Louis encephalitis virus, however, with virus given intraperitoneally, protection was not observed beyond 3 days post-inoculation, when significant neural invasion first occurred (Mathews & Roehrig, 1984) .
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